Malignant pilomatricoma: an immunohistochemical study with antihair keratin antibody

Article Abstract:

Pilomatricoma is generally benign. This tumor develops in the cells of the hair matrix, and the tumor cells themselves tend to differentiate into a form resembling hair cortical cells. However, it is possible for a pilomatricoma to become cancerous; only 29 instances of this uncommon event have been reported in the medical journals. The authors report the case of an 88-year-old woman who died of complications of cancer and its treatment; only after her death was the cancer found to be malignant pilomatricoma. The patient was seen originally because of gradually progressing edema, the accumulation of fluid in the tissues of her right leg. Numerous hard nodules, between 1 and 2 centimeters, were found in the patient's right inguinal region upon physical examination. Similar nodules were not found in other regions, including the abdomen and rectum. A biopsy was performed, and microscopic evaluation of the specimen suggested that the nodule was a lymph node contaminated with cancerous cells from a squamous cell carcinoma. A primary squamous cell carcinoma which could account for these nodules was not found, but the patient was treated with chemotherapy and radiation therapy. Two years after treatment, the patient died of kidney failure. At the time of her death, metastatic cancer could be identified in the skin of her abdomen and in the tissues behind the peritoneal cavity. At autopsy, specimens were obtained for further study. Microscopic specimens were stained using antibodies specific for hair keratin. (The staining properties of this antibody are different from those of other forms of keratin such as epidermal skin keratin.) This hair antibody was found to stain normal hair matrix and the patient's tumor cells; the antibody did not stain components of normal skin, indicating that the tumor was biochemically similar to the hair matrix and was therefore a pilomatricoma. (Consumer Summary produced by Reliance Medical Information, Inc.)

Physiological aspects, Skin cancer

---

Six new monoclonal antibodies to serous, mucinous, and poorly differentiated ovarian adenocarcinomas

Article Abstract:

The advent of monoclonal antibodies has dramatically broadened the range of possibilities for immunohistochemistry. Whereas previously antigens had to be identified and purified before antibodies could be made, now it is possible to obtain highly specific monoclonal antibodies against minority antigens hidden in a complex mixture. The technique of monoclonal antibody preparation was used to make antibodies against an extract of ovarian serous adenocarcinoma. Six antibodies were obtained with a high degree of specificity. None of the antibodies reacted with clear cell or endometrioid carcinoma, but all six recognized all of the serous and mucinous ovarian adenocarcinomas tested. They also recognized 82 percent of the poorly differentiated carcinomas tested. These antibodies did not recognize normal ovarian tissue. The staining patterns of these antibodies indicate that they recognize antigens of the ovarian cancer cells that are distinct from the antigens that have already been described in the literature, and thus the antibodies may prove useful in the diagnosis of occult ovarian cancer. (Consumer Summary produced by Reliance Medical Information, Inc.)

Research, Diagnosis, Ovarian cancer, Monoclonal antibodies, Adenocarcinoma, Immunohistochemistry

---

Similar abstracts:

• Abstracts: Malignant plasma cell tumors in human immunodeficiency virus-infected patients. Cutaneous Hodgkin's disease in a patient with human immunodeficiency virus infection
• Abstracts: Gastric carcinoids and their precursor lesions: a histologic and immunohistochemical study of 23 cases. An analysis of immunocomplexes for the detection of the early stages of colon cancer
• Abstracts: Evaluation and management of menstrual dysfunction in athletes. A 21-year-old woman with menstrual irregularity
• Abstracts: DNA polymerase-alpha as a putative early relapse marker in non-small cell lung cancer: an immunohistochemical study

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.